• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WuXi NextCODE to accelerate growth of global platform for genomic data

WuXi NextCODE to accelerate growth of global platform for genomic data

May 4, 2017
CenterWatch Staff

WuXi NextCODE, a contract genomics organization (CGO) building the global standard platform for genomic data, has closed a $75 million Series B financing from the company's existing investors and partners.

The financing was co-led by Temasek and Yunfeng Capital. Other investors include Amgen Ventures, a corporate venture capital fund established by Amgen, and 3W Partners, a Greater China/cross-border focused private equity firm.

"We are building the world's leading genomic data platform, applying genome sequencing data at scale to improve human health and wellness around the world," said Hannes Smarason, CEO of WuXi NextCODE. "Our rapidly expanding business is serving the world's leading precision medicine initiatives as well as genome-driven diagnostics and wellness enterprises worldwide."

"Genomics is the crossroad where data and biology meet," said Dr. Ge Li, chairman of WuXi NextCODE and founder and chairman of WuXi AppTec. "Through its comprehensive capabilities for digitizing, managing and analyzing genome data, WuXi NextCODE is uniquely positioned to build the open access and capability platform that enables any organization or individual to benefit from genomic big data."

WuXi NextCODE will focus the use of proceeds from this round on advancing the commercialization of its consumer solutions for the China market; to further strengthen its global leadership position in informatics; and to expand its capabilities in artificial intelligence and deep learning.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing